# Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes

> **NCT01622478** · — · COMPLETED · sponsor: **Gangnam Severance Hospital** · enrollment: 120 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** Sentinel lymph node biopsy
- **DRUG:** Neoadjuvant chemotherapy
- **PROCEDURE:** complete axillary lymph node dissection
- **PROCEDURE:** positron emission tomography and ultrasonogram

## Key facts

- **NCT ID:** NCT01622478
- **Lead sponsor:** Gangnam Severance Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-06
- **Final completion:** 2009-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2012-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01622478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01622478, "Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01622478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*